A research team has created a new mouse model of a common form of muscular dystrophy with the potential of rapidly distinguishing promising therapeutic drugs from those unlikely to be successful. In their report published in Nature Communications they also describe testing a novel antisense oligonucleotide drug - a synthetic nucleic acid strand that prevents transcription of a protein by binding to its mRNA molecule - that may more effectively block production of aberrant proteins.
"This novel fluorescent model allows monitoring of therapeutic drug activity simply by using a camera to take pictures of living mice," says senior author of the report. "By crossing an established mouse model of myotonic dystrophy type 1 with one that expresses either a red or green fluorescent protein in muscle, depending on the splicing of a target RNA sequence, we developed a model in which muscles appear mostly green before treatment and transition to mostly red after successful treatment."
The most common form of adult-onset muscular dystrophy, myotonic dystrophy has two subtypes. Type 1 (DM1) affects RNA splicing, the process that removes non-coding segments from an RNA molecule and determines precisely which protein is produced. The DM1-associated mutation affects splicing of RNAs encoding several important proteins in skeletal muscles along with proteins involved in insulin metabolism and cardiac function. Determining with existing animal models whether potential DM1 therapies could correct this aberrant splicing requires molecular analysis of muscle tissue, which is expensive, time consuming and requires a large number of animals to test each new drug.
The team adapted an existing fluorescent-protein-based system developed for cellular studies into one in which the proteins were expressed only in skeletal muscle tissue. In this "bi-transgenic" mouse model, muscle fibers affected by the aberrant RNA splicing of DM1 fluoresce green while those in which splicing is appropriate fluoresce red. The ratio between the red and green signals indicates whether or not a potential therapy is correcting aberrant splicing.
The investigators first tested their model using an existing antisense oligonucleotide (ASO) that targets the RNA-mediated disease process in DM1. They were surprised to observe an increase of the red/green ratio beginning as early as three days after the ASO was injected into the animals' muscles, an increase that persisted for several weeks. Muscle tissue analysis 49 days after injection confirmed correction of the aberrant RNA splicing. Subcutaneous injection with another ASO known to correct RNA splicing defects in the original DM1 model produced a therapeutic effect, as indicated by the increased red/green ratio, as early as 14 days after the first of four injections, an effect that became more pronounced through the eighth dose on day 25.
Because previous studies testing ASOs as potential DM1 therapies were limited by a lack of sufficient drug concentration in muscle tissue, the team tested a technology called ligand-conjugated antisense (LICA), which enhances delivery of a subcutaneously injected ASO to muscles throughout the body. Their LICA ASO - the first to be tested as a potential DM1 treatment - demonstrated therapeutic activity twice as fast as the unconjugated version of the same ASO, indicating a two-fold greater potency of the LICA drug.
"Our results support further development of LICA technology for the treatment of DM1. In addition to new ASOs, other treatment strategies such as small-molecule candidate drugs, siRNAs and protein-based therapies also could be tested using this model. Long term it would be ideal for testing gene-editing therapeutic approaches, as they become available," says the author. "Faster identification of promising therapies and early rejection of failed candidates will help make effective treatments available to patients sooner and at lower developmental costs."
https://www.massgeneral.org/about/pressrelease.aspx?id=2323
https://www.nature.com/articles/s41467-018-07517-y
Latest News
A new gene-editing system
By newseditor
Posted 23 May
How ketamine's molecular ac…
By newseditor
Posted 23 May
Therapeutic avenues in bone…
By newseditor
Posted 23 May
Linking key nutrients with…
By newseditor
Posted 23 May
Ferroptosis in fatal COVID-…
By newseditor
Posted 22 May
Other Top Stories
Cartilage-like protein hydrogel shows promise for joint injuries
Read more
How somatic mutations cause intracranial aneurysms
Read more
Gene therapy to treat developmental epilepsy syndrome
Read more
Pain perceived differently in people with Alzheimer's Disease
Read more
The mechanism of coagulopathy
Read more
Protocols
Efficient expansion and CRI…
By newseditor
Posted 21 May
Massively parallel in vivo…
By newseditor
Posted 20 May
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Methods for making and obse…
By newseditor
Posted 15 May
Mime-seq 2.0: a method to s…
By newseditor
Posted 13 May
Publications
Patterning and folding of i…
By newseditor
Posted 23 May
Peri-ictal activation of do…
By newseditor
Posted 23 May
Ancestry, ethnicity, and ra…
By newseditor
Posted 23 May
Ketamine can produce oscill…
By newseditor
Posted 23 May
Upregulation of neuronal ER…
By newseditor
Posted 23 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar